Levamlodipine Besylate/Valsartan

苯磺酸左旋氨氯地平/缬沙坦

Report date: 2024/04/29 20:00:40

Base Information

Drug NameLevamlodipine Besylate/Valsartan
Drug Alias NameLevosartan
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsVoltage-gated calcium channel blockers
TargetsAngiotensin II Receptor Type 1Voltage-gated calcium channel
Therapy Area/IndicationsEssential HypertensionHypertension
Global Approved IndicationsHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2013/10/01
Country/TerritorySouth KoreaMainland China
CombinationsYes ValsartanLevamlodipine Besylate
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAhn-Gook Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang Hemukang Pharmaceutical Technology Co LtdAhn-Gook Pharmaceutical Co LtdBeijing Baiao Pharmaceuticals Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsEssential HypertensionHypertension
Inactive IndicationsN/A

Other Information

ATC CodeC09DB01
Related LinksN/A